SARS-CoV-2 vaccination in solid-organ transplant recipients: What the clinician needs to know.

Détails

Ressource 1Télécharger: 34450686_BIB_BC93C5A203F2.pdf (379.52 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC 4.0
ID Serval
serval:BIB_BC93C5A203F2
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
SARS-CoV-2 vaccination in solid-organ transplant recipients: What the clinician needs to know.
Périodique
Transplant international
Auteur⸱e⸱s
Giannella M., Pierrotti L.C., Helanterä I., Manuel O.
ISSN
1432-2277 (Electronic)
ISSN-L
0934-0874
Statut éditorial
Publié
Date de publication
10/2021
Peer-reviewed
Oui
Volume
34
Numéro
10
Pages
1776-1788
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
In response to the COVID-19 pandemic, SARS-CoV-2 vaccines have been developed at an unparalleled speed, with 14 SARS-CoV-2 vaccines currently authorized. Solid-organ transplant (SOT) recipients are at risk for developing a higher rate of COVID-19-related complications and therefore they are at priority for immunization against SARS-CoV-2. Preliminary data suggest that although SARS-CoV-2 vaccines are safe in SOT recipients (with similar rate of adverse events than in the general population), the antibody responses are decreased in this population. Risk factors for poor vaccine immunogenicity include older age, shorter time from transplantation, use of mycophenolate and belatacept, and worse allograft function. SOT recipients should continue to be advised to maintain hand hygiene, use of facemasks, and social distancing after SARS-CoV-2 vaccine. Vaccination of household contacts should be also prioritized. Although highly encouraged for research purposes, systematic assessment in clinical practice of humoral and cellular immune responses after SARS-CoV-2 vaccination is controversial, since correlation between immunological findings and clinical protection from severe COVID-19, and cutoffs for protection are currently unknown in SOT recipients. Alternative immunization schemes, including a booster dose, higher doses, and modulation of immunosuppression during vaccination, need to be assessed in the context of well-designed clinical trials.
Mots-clé
SARS-CoV-2, immunogenicity, mRNA vaccine, organ transplantation, prevention, safety
Pubmed
Web of science
Open Access
Oui
Création de la notice
15/09/2021 9:42
Dernière modification de la notice
23/11/2022 7:14
Données d'usage